07:00 , May 29, 2006 |  BC Week In Review  |  Company News

Abraxis management update

Abraxis BioScience Inc. (ABBI), Los Angeles, Calif.   Business: Cancer, Drug delivery, Generics   Hired: Richard Maroun as chief administrative officer, formerly general counsel and CP of corporate development at American BioScience Inc.; Thomas Silberg...
07:00 , Apr 24, 2006 |  BC Week In Review  |  Company News

American Bioscience, American Pharmaceutical Partners deal

American BioScience completed its previously announced merger with its APPX majority-owned subsidiary in a stock deal to form Abraxis BioScience Inc. (see BioCentury, Dec. 5, 2005). The newco trades on NASDAQ under the symbol ABBI....
08:00 , Dec 5, 2005 |  BC Week In Review  |  Company News

American Bioscience, American Pharmaceutical Partners deal

American BioScience will merge with its APPX majority-owned subsidiary in a stock deal. American BioScience shareholders, who currently own 64.4% of APPX, will own 83.5% of the combined entity. The deal is expected to close...
08:00 , Nov 21, 2005 |  BC Week In Review  |  Company News

American Bioscience, Taiho deal

American BioScience granted Taiho exclusive Japanese development and commercialization rights to Abraxane paclitaxel to treat breast, lung, gastric and other solid tumors. American BioScience could receive up to $50 million in an upfront payment and...
03:02 , Nov 17, 2005 |  BC Extra  |  Company News

American BioScience, Taiho Abraxane deal

American BioScience (Santa Monica, Calif.) granted Taiho (Tokyo, Japan) exclusive Japanese development and commercialization rights to Abraxane paclitaxel to treat breast, lung, gastric and other solid tumors. American BioScience could receive up to $50 million...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel: Phase I data

Data from an open-label, U.S. Phase I trial in 39 patients showed that the MTDs of ABI-007 were 100 and 150 mg/m 2 for lightly and heavily pretreated patients, respectively. Patients received an average of...
07:00 , Jun 20, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel regulatory update

The partners submitted a marketing application to Health Canada for Abraxane to treat metastatic breast cancer. The solvent-free nanoparticle albumin-bound formulation of paclitaxel was approved in the U.S. for the same indication in January. (see...
07:00 , May 9, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel: Completed Phase II enrollment

The partners completed enrollment of 30 patients in an open-label, U.S. Phase II trial. The patients are receiving Adriamycin plus Cytoxan every 2 weeks for 4 cycles followed by 260 mg/m 2 Abraxane in a...
07:00 , Apr 18, 2005 |  BC Week In Review  |  Clinical News

Coroxane: Phase I data

Data from the Phase I SNAPIST-1 trial in 23 patients showed that the patients receiving IV injection of <70 mg/m 2 of Coroxane were free from significant adverse events. Data were presented at the Cardiovascular...
08:00 , Jan 10, 2005 |  BC Extra  |  Financial News

APPX still climbing on Abraxane approval

American Pharmaceutical Partners (APPX) gained $11.01 (28%) to $49.72 on 13.3 million shares Monday after adding $4.78 (14%) to $38.71 on Friday when FDA approved its Abraxane to treat metastatic breast cancer. Abraxane is a...